Xanthic Biopharma (CSE:xTHC) is pleased to announce a strategic partnership with ABH Pharma Inc. (“ABH”), a leading FDA-registered and GMP-certified manufacturer of in-house branded and private label dietary supplements in the United States. Through its partnership with Xanthic, ABH will offer “Xanthic Powered” CBD-infused products to customers across its broad range of dietary supplements. These products will be sold by a variety of well-known brick-and-mortar retailers and e-commerce websites.

Using the same non-cannabis and non-hemp CBD that powers Xanthic CBD Water, ABH is able to offer CBD-infused dietary supplement products for sale alongside its non-CBD products to customers. ABH manufactures products under its own brand names as well as under private label brands. All products using the Xanthic CBD powder will bear the catchphrase “Powered by Xanthic Solubles”. (See Xanthic press release dated May 29, 2018 for more detail on Xanthic CBD Water).

Frank Cantone, President of ABH, stated: “We are excited to remain on the forefront of the nutraceuticals industry with this development. The Xanthic partnership allows us to provide our customers with a competitive advantage, continuing to meet the evolving demands of consumers.”

Tim Moore, CEO of Xanthic, commented: “Our partnership with ABH represents an important step for Xanthic. It allows us to introduce “Powered by Xanthic” CBD powder technology to a broader consumer audience across the United States. The ABH portfolio of state-of-art dietary supplements is a perfect partner for our technology.”

About ABH Pharma

ABH is an industry leader in the U.S. in the realm of dietary supplement manufacturing. ABH offers full turn-key services from formulation to bottling and order fulfillment. ABH takes pride in helping its clients’ dreams of owning a world class supplement brand come true. Mastering both custom formulations and their growing private label line, ABH has set the status quo high.  www.abhpharma.com

About Xanthic

Xanthic, through its wholly-owned operating subsidiary, Xanthic Biopharma Limited, provides valuable intellectual property to cannabis industry participants, enabling its strategic partners to produce high quality, innovative, non-combustible cannabis and cannabis-infused products.  Using a proprietary process, Xanthic empowers its strategic partners to deliver superior cannabinoid solubility, improved bioavailability, accurate micro-dosing, and greater consistency versus competitive infused products. Through its investment in Xanthic Beverages, Xanthic has access to non-cannabis derived CBD-infused products that qualify for distribution outside of the cannabis dispensary network and into mainstream retail. www.xanthicbio.com


This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. There is no assurance that the strategic partnership with ABH will successfully produce benefits for Xanthic. Although such forward-looking statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances, except as required pursuant to applicable securities laws.

For further information: or questions, contact: Tim Moore, CEO, Xanthic Biopharma Inc., timm@xanthicbiopharma.com, Phone: 1-647-966-6536, info@xanthicbiopharma.com

Click here to connect with Xanthic Biopharma (CSE:xTHC) for an Investor Presentation.

Source: www.newswire.ca

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less